Genprex announced that its collaborators will present positive preclinical data for Reqorsa Gene Therapy (quaratusugene ozeplasmid) at the 2026 AACR Annual Meeting. The findings advance the understanding of TUSC2's therapeutic mechanisms in lung cancer and identify TROP2 and PTEN as potential biomarkers of resistance to TUSC2 gene therapy in non-small cell lung cancer, which could refine patient selection strategies.

Atara Biotherapeutics announced that a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the Complete Response Letter (CRL) issued on January 9, 2026, for the Biologics License Application (BLA) of EBVALLO™. This meeting is a critical step for the company to address the FDA's concerns and determine the next steps for the drug's potential approval.

BioAtla announced a formal process to explore strategic alternatives, including asset sales and partnerships, and implemented a 70% workforce reduction to reduce costs. The company is also navigating an ongoing Nasdaq delisting review and is in discussions to revise a previously announced $40 million private placement. Concurrently, the Chief Financial Officer was replaced.

Werewolf Therapeutics, Inc. announced on February 24, 2026, its intention to explore strategic alternatives. The company has engaged Piper Sandler & Co. as its exclusive financial advisor to assist in this strategic evaluation.

Genprex announced the issuance of patents in Japan and Europe for Reqorsa® Gene Therapy in combination with PD-L1 and PD-1 antibodies to treat cancer, bolstering its intellectual property portfolio. The company also provided an update on its Phase 1/2 Acclaim-3 clinical trial, which is evaluating REQORSA in combination with Genentech's Tecentriq for extensive stage small cell lung cancer, with interim analysis for the Phase 2 expansion expected in the second half of 2026.

Genprex announced that IP Australia has issued a Notice of Acceptance for a patent application covering the use of Reqorsa® Gene Therapy in combination with PD-L1 antibodies for cancer treatment, which would strengthen IP for its Acclaim-3 trial. The company also opened an additional clinical trial site for its Phase 1/2 Acclaim-3 study evaluating REQORSA with Genentech’s Tecentriq in extensive stage small cell lung cancer (ES-SCLC), with plans for more sites to expedite enrollment. An interim analysis for the Phase 2 portion, which has FDA Fast Track and Orphan Drug Designations, is expected in the second half of 2026.

IO Biotech, Inc. has approved a restructuring and workforce reduction plan, effective January 21, 2026, to significantly reduce its global workforce and operating expenses while exploring strategic alternatives. The company expects to incur $2.4 million to $2.6 million in one-time charges related to this plan. Additionally, the Chief Medical Officer's employment will conclude on February 15, 2026, and Raymond James & Associates, Inc. has been retained as the exclusive financial advisor for the strategic alternatives exploration.

IO Biotech, Inc. announced on January 21, 2026, its intention to explore strategic alternatives. This announcement was made via a press release, which is included as an exhibit to this Current Report on Form 8-K.